Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk Individuals

Ki vehet részt

• Are aged 18 or more
• Have a cumulative 3-year risk of developing any cancer ≥ 4% (including the situation specific cancers + other cancers) defined as follows:; Situations at increased risk of breast cancer; Women carrying germline pathogenic (P) or likely pathogenic (LP) variants of BRCA1, BRCA2, TP53, PALB2, PTEN, CDH1 genes without prophylactic mastectomy, aged ≥ 40 years, or; Men with germline (P) or (LP) variants in the BRCA2 gene, aged ≥ 40 years, or; Women with a personal history of an histological atypical breast lesion in the past 5 years and aged ≥ 50 years, or; Women with a personal history of unilateral breast cancer (including ductal carcinoma in situ) diagnosed more than 5 years before inclusion, and currently aged ≥ 60 years, or; Women who received chest radiotherapy before age 30 years and currently aged ≥ 25 years, or; Women with an invasive breast cancer risk > 2.5% over the next 5 years, as defined by risk scores +/- genotyping, and aged ≥ 50 years, or; Individuals identified at increased risk in MyPeBS trial (> 2.5% over the next five years) (www.mypebs.eu) can be eligible for the study, if aged ≥ 50 years, or; Situations at increased risk of gynaecological cancer; Women with a Lynch syndrome - germline (P) or (LP) variants in hMLH1, MSH2, hMLH6, PMS2, and aged ≥ 30 years, or; Women carrying germline (P) or (LP) variants of BRCA1, BRCA2, PALB2, RAD51C or RAD51D, PTEN genes without prophylactic oophorectomy, aged ≥ 40 years, or POLE and POLD1, and aged > 30 years; or SMARCA4 or DICER1 and aged > 18 years or; Situations at increased risk of colorectal cancer; Men or women with a Lynch syndrome - germline (P) or (LP) variants in hMLH1, MSH2, hMLH6, PMS2, APC, POLE, POLD1, BMPR1A, SMAD4 or biallelic MuTYH genes, and aged ≥ 40 years, or; Individuals with an increased risk of colorectal cancer defined by the following criteria and aged ≥ 50 years, or; First-degree relative diagnosed with colorectal cancer before the age of 60 years, or; Two or more 1st degree relatives diagnosed with colorectal cancers at any age, or; Personal history of any colorectal adenoma before the age of 50 years or adenomatous polyps > 1 cm, villous adenomas, dysplastic adenomas, or ≥ 3 adenomatous polyps after the age of 50 years, or; Inflammatory Bowel Disease (Crohn's Disease; Ulcerative Colitis) after the age of 50 years, or; Situations at increased risk of upper gastrointestinal cancers; Carriers of an STK11 or CDH1 germline (P) or (LP) variants and aged > 30, or; Individuals with an increased risk of esophageal adenocarcinoma: Barrett's esophagus with high-grade dysplasia, or; Situations at increased risk of hepatic cancers; Individuals at increased risk of hepatocellular carcinoma because of documented liver fibrosis or cirrhosis (whether secondary to non-alcoholic steatohepatitis, alcohol-related, or virus-related), or; Situations at increased risk for pancreatic cancers; Patients with a family history with > 2 pancreatic cancers in close relatives and aged >50 or; Chronic pancreatitis and aged >50 or carriers of PRSS1 or SPINK1 germline (P) or (LP) variants or; Patients at increased risk of pancreatic cancer based on a composite score or; Carriers of CDKN2A germline (P) or (LP) variants or; Carriers of germine (P) or (LP) variants in BRCA2, ATM, BRCA1, PALB2, or Lynch syndrome-associated gene alterations with a first-degree or multiple family history of pancreatic ductal carcinoma (PDAC) or; Patients with a Peutz-Jeghers syndrome (STK11 germline (P) or (LP) variants) or; Situations at increased risk of lung cancer; History of heavy smoking > 20 pack-years among active or previous smokers who have quitted up to 10 years ago, and aged ≥ 50 years, or; Situations at increased risk of skin cancers except basal-cell carcinomas; Carriers of germline (P) or (LP) variants in CDKN2A/CDK4 or BAP1 genes, aged ≥ 50 years or; Carriers of germline (P) or (LP) variants of genes that predispose to skin cancers (Xeroderma pigmentosum, etc…) or; Situations at increased risk of head and neck cancers; Individuals with high-grade dysplasia or carcinoma in situ of the upper aero digestive tract within the last 10 years, and aged ≥ 50 years, or; Individuals with oral lichen planus diagnosed more than 10 years ago, and aged ≥ 50 years or; Previous history of a head and neck cancer in complete remission for ≥ 5 years, aged ≥ 50 years, and at least one of the following criteria:; Current or former smoker > 10 pack-years Current or former alcohol consumption > 14 units/week; Situations at increased risk of mesothelioma; Individuals with a history of relevant professional exposure to asbestos, and/or germline (P) or (LP) variants in BAP1, and aged ≥ 50 years, or; Situations at increased risk of kidney cancer; Carriers of germline (P) or (LP) variants in the BAP1, VHL, FH, cMET, FLCN, SDH-B genes, and aged ≥ 50 years, or; Situations at increased risk of prostate cancer; Men aged ≥ 40 year with any of the following:; Strong family history: a first- or second-degree relative with metastatic prostate cancer, ovarian cancer, male breast cancer, female breast cancer aged ≤ 45 years, colorectal or endometrial cancer aged ≤ 50 years, pancreatic cancer or two or more first- or second-degree relatives with breast, prostate (but not clinically localized grade group 1), colorectal or endometrial cancer at any age, or; Carriers of germline (P) or (LP) variants in BRCA1, BRCA2, ATM, HOXB13, hMLH1, MSH2, hMLH6, and PMS2, and aged > 45; Situations at increased risk of urothelial cancers; History of heavy smoking > 30 pack-years, among active or previous smokers who have quitted up to 10 years ago, and aged ≥ 50 years, or; Lynch syndrome with a germline (P) or (LP) variants in hMLH1, MSH2, hMLH6, PMS2, and aged ≥ 40 years, or; Situations at increased risk of endocrine cancers; Increased risk of pheochromocytoma paraganglioma in individuals with germline (P) or (LP) variants in RET, VHL, SDHB, SDHD, and aged ≥ 35 years, or; Multiple endocrine neoplasia syndrome in individuals with germline (P) or (LP) variants in RET or MEN1, and aged ≥ 40 years, or; Situations at increased risk of hematologic malignancies; Individuals aged ≥ 50 years with any of the following:; Clonal hematopoiesis of indeterminate potential, or; Aplastic anemia, or; Predisposing genetic alterations (P) or (LP) variants in GATA2, RUNX1, ANKRD26, ETV6, TP53, CEBPA, or DDX41 genes, or copy number variation of chromosome 14q32 region (CNVdup14), or; Patients who received high doses of platinum or other compounds who are estimated to have a > 2% risk of secondary hematological malignancies at 3 years, or; Situations at increased risk of several cancer types; Germline deleterious mutations of TP53 (Li-Fraumeni syndrome), and aged > 18 or; Germline deleterious (P) or (LP) variants in PTEN, Cowden syndrome, and other PTEN-opathies, aged ≥ 30 years, or; Personal history of allogenic organ transplantation at least five years before the inclusion, with long-term ongoing immunosuppressive treatment, and aged ≥ 50 years, or; Chronic HIV carriers aged > 50, or; Situations at increased risk of second malignancy in individuals treated for a childhood cancer; Brain radiation therapy during childhood, and aged ≥ 18 years, or; Childhood malignancy which required chemotherapy and/or radiation therapy, and aged ≥ 40 years, or
• Beyond the situations described previously, the following individuals are also eligible for LEAH:; Increased risk of neoplasia linked to an underlying professional exposure, with a specific cancer risk estimated to be at least 2 % at 3 years, and aged ≥ 50 years, or; Other situation: Any particular situation with accumulation of several risk factors likely to induce cancer with a specific risk of cancer estimated at least 2% at 3 years
• Participants with a personal cancer or hematological malignancy history are allowed if they are in complete remission at least 5 years from the primary diagnosis
• All participants must understand spoken and written French language,
• All participants must agree to comply with the protocol requirements,
• All participants must understand, sign, and date the written informed consent form prior to any protocol-specific procedures performed
• All participants must be able to access internet through their telephone or a computer
• Individuals seen for a rapid diagnostic procedure at the center as part of the Instadiag programme, that led to a diagnosis of a benign condition
• Who do not have a high risk situation as defined previously
• Agree to participate
• Aged >18
• They must understand spoken and written French language,
• They must agree to comply with the protocol requirements,
• They must understand, sign, and date the written informed consent form prior to any protocol-specific procedures performed
• They must be able to access internet through their telephone or a computer

Ki nem vehet részt

• Known prior diagnosis of cancer or hematological malignancy within the past 5 years except for non-melanoma skin cancers, in situ cervical cancers and for patients with germline TP53 alterations,
• Acute exacerbation of an autoimmune condition requiring escalation in medical therapy within 14 days prior to enrolment,
• Received a blood transfusion within the last week before inclusion
• Presence of signs or symptoms of cancer at enrolment,
• Any medical condition with a high likelihood of mortality within three years,
• Physical or psychological conditions considered not to be compatible with the study and not likely to comply with follow up requirements,
• Women carriers of (P) or (LP) variants in BRCA1, BRCA2, PALB2, gene considering prophylactic mastectomy in a near future or aged less than 40 years (since their absolute risk of cancer is lower than the expected threshold)
• Individuals under guardianship or deprived of their liberty by a judicial or administrative decision or incapable of giving their consent,